REFERENCE FILE
Dulaglutide
Examine the reference details alongside the questions and dated sources.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- GLP-1 receptor agonist fusion protein.
- Evidence
- Randomized studies.
- Limitations
- No weight-management indication.
- Safety
- Not recommended for severe gastroparesis.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Trulicity: specified type 2 diabetes populations.
READING NOTES
Questions for a closer look
Read a dulaglutide outcome sentence with its time expressions highlighted. Locate the event that starts measurement, the occasion when the outcome is assessed and any interval over which experiences are accumulated. Translate each expression into an instruction someone could follow when reviewing a record. Then compare those instructions with the sentence's wording. A question about an experience during an interval differs from a question about a condition at its end. Ask which instruction would produce the reported quantity, without supplying an unreported history. Finish by attaching the relevant timing phrase to your description of the result.
Questions to investigate
- Which event starts measurement, and which occasion determines the reported outcome?
- Does the wording concern an interval or a condition at its end?
- What timing phrase belongs beside the result when I describe it?
Sources for this file
- TRULICITYNLM · Checked
MED CONSUMER WATCH · RESEARCH
Read the evidence behind the question.
Browse reference files or follow a study analysis from its question to its limitations.